Trials

Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MKMK)in Patients with Advanced Cancer

Cancer type: Multiple diagnosis

Phase: I

Principal Investigator: Dajani Olav

Country: NO

Keywords: Norway, Oslo University Hospital, Recurrent glioblastoma, multiforme, Hormone resistant prostate cancer, Relapsed ovarian carcinoma, Breast cancer, Prostate cancer, Oslo

Status: Completed

Link to Clinicaltrials.gov: http://www.clinicaltrials.gov/ct2/show/NCT01295632?term=MK8669-049&rank=1